REG - Hikma Pharmaceutical - Result of AGM <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

19/05/2017 14:45

RNS Number : 7108F
Hikma Pharmaceuticals Plc
19 May 2017
Hikma Pharmaceuticals PLC 
Voting Results of 2017 Annual General Meeting
LONDON, 19 May 2017 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 19 May 2017 commenced at 10:00 am today. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 19 were passed as ordinary resolutions and Resolutions 20 to 23 were passed as special resolutions. 
As previously announced, Mr. Michael Ashton retired from the Board at the close of the AGM.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the UK Listing Authority for publication through the Listing Authority's Document Viewing Facility. 
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 7 April 2017) is set out below. The number of Ordinary Shares in issue on 19 May 2017 was 240,380,475.
Resolution
Votes For
%
Votes Against
%
Withheld
Total Cast
1. To receive the 2016 report and accounts
197,423,759
99.84%
319,920
0.16%
6,643
197,750,322
2. To approve a final dividend of 22 cents per share
197,743,879
100.00%
0
0.00%
6,443
197,750,322
3. To re-appoint PricewaterhouseCoopers LLP as auditors
197,741,251
100.00%
905
0.00%
8,166
197,750,322
4.To authorise the Audit Committee to determine the auditors' remuneration 
197,688,953
99.97%
53,203
0.03%
8,166
197,750,322
5. To elect Nina Henderson as a director
197,534,627
99.89%
208,786
0.11%
6,854
197,750,267
6. To re-elect Said Darwazah as a director
193,519,353
98.05%
3,848,526
1.95%
382,442
197,750,321
7. To re-elect Mazen Darwazah as a director
195,813,592
99.21%
1,551,895
0.79%
384,835
197,750,322
8. To re-elect Robert Pickering as a director
197,076,319
99.66%
667,559
0.34%
6,443
197,750,321
9.To re-elect Ali Al-Husry as a director
196,769,085
99.57%
857,947
0.43%
123,290
197,750,322
10. To re-elect Dr. Ronald Goode as a director
195,703,815
98.97%
2,039,923
1.03%
6,584
197,750,322
11. To re-elect Patrick Butler as a director 
197,506,890
99.88%
236,848
0.12%
6,584
197,750,322
12. To re-elect Dr. Jochen Gann as a director
196,795,912
99.58%
830,979
0.42%
123,431
197,750,322
13. To re-elect John Castellani as a director
197,586,602
99.92%
157,277
0.08%
6,443
197,750,322
14. To re-elect Dr. Pamela Kirby as a director
195,665,777
98.96%
2,053,602
1.04%
6,468
197,725,847
15. To approve the directors' remuneration policy
169,053,856
86.39%
26,622,257
13.61%
2,074,207
197,750,320
16. To approve the remuneration report for the year ended 31 December 2016
193,651,599
97.93%
4,091,754
2.07%
6,968
197,750,321
17. To approve the extension of the effective period of the Executive Incentive Plan 
170,276,525
86.12%
27,450,966
13.88%
22,830
197,750,321
18. To approve the increase of the aggregate directors' fee limit
197,640,307
99.98%
45,091
0.02%
64,924
197,750,322
19. Authority to allot shares
170,146,304
86.21%
27,221,034
13.79%
382,984
197,750,322
20. To dis-apply pre-emption rights for general purposes
196,872,145
99.56%
869,023
0.44%
9,154
197,750,322
21. To dis-apply pre-emption rights for an acquisition or other capital investment
173,591,716
87.79%
24,149,939
12.21%
8,666
197,750,321
22. To authorise the Company to purchase its own shares
197,014,413
99.66%
676,265
0.34%
59,643
197,750,321
23. To authorise the Company to hold general meetings on no less than 14 clear days' notice
187,053,655
94.82%
10,213,802
5.18%
482,864
197,750,321
Declaration of final dividend
The dividend of 22 cents per share will be paid on 25 May 2017 to shareholders on the register on 7 April 2017. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.2898 to 1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary
+44 20 7399 2670
Susan Ringdal
VP for Investor Relations and Strategy
+44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast-growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa ("MENA") and Europe. In 2016, Hikma achieved revenue of $1,950million and profit attributable to shareholders of $155 million. In the United States, Hikma operates through its wholly owned subsidiary, West-Ward Pharmaceuticals Corp., with operations based in New Jersey, Ohio and Tennessee. For more information visit www.hikma.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RAGSFEFDUFWSELI